Research programme: hepatitis C virus therapy - Hybrigenics/XTL
Latest Information Update: 14 Sep 2007
At a glance
- Originator Hybrigenics; XTL Biopharmaceuticals
- Developer Hybrigenics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 27 Sep 2004 This programme is still in active development
- 22 Sep 2000 Preclinical development for Hepatitis C in USA (Unknown route)